A detailed history of Citigroup Inc transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Citigroup Inc holds 4,883 shares of NVCT stock, worth $35,645. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,883
Previous 1,382 253.33%
Holding current value
$35,645
Previous $11,000 172.73%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$5.98 - $8.25 $20,935 - $28,883
3,501 Added 253.33%
4,883 $30,000
Q1 2024

May 10, 2024

BUY
$6.69 - $11.0 $1,833 - $3,014
274 Added 24.73%
1,382 $11,000
Q4 2023

Feb 09, 2024

BUY
$7.85 - $11.78 $8,658 - $12,993
1,103 Added 22060.0%
1,108 $9,000
Q3 2023

Nov 09, 2023

SELL
$12.89 - $16.29 $26,218 - $33,133
-2,034 Reduced 99.75%
5 $0
Q2 2023

Aug 10, 2023

BUY
$12.62 - $18.4 $25,732 - $37,517
2,039 New
2,039 $32,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $107M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.